Xenon Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ CA98420N1050

Introduction

This page provides a comprehensive analysis of the known insider trading history of Empfield James R.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Empfield James R. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:XENE / Xenon Pharmaceuticals Inc. EVP, Drug Discovery 10,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Empfield James R.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases XENE / Xenon Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in XENE / Xenon Pharmaceuticals Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-08-15 XENE EMPFIELD JAMES R. 10,000 2.4824 10,000 2.4824 24,824 359 12.1 96,176 387.43

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XENE / Xenon Pharmaceuticals Inc. Insider Trades
Insider Sales XENE / Xenon Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in XENE / Xenon Pharmaceuticals Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2022-08-12 XENE EMPFIELD JAMES R. 35,868 38.0800 35,868 38.0800 1,365,853 89 33.0600 -180,057 -13.18
2022-08-12 XENE EMPFIELD JAMES R. 21,875 38.6800 21,875 38.6800 846,125
2022-03-07 XENE EMPFIELD JAMES R. 1,805 30.6200 1,805 30.6200 55,269
2022-03-07 XENE EMPFIELD JAMES R. 31,048 30.5400 31,048 30.5400 948,206
2022-03-04 XENE EMPFIELD JAMES R. 18,315 30.7900 18,315 30.7900 563,919

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XENE / Xenon Pharmaceuticals Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Empfield James R. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-08-16 2022-08-12 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
S - Sale -21,875 10,000 -68.63 38.68 -846,125 386,800
2022-08-16 2022-08-12 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
S - Sale -35,868 31,875 -52.95 38.08 -1,365,853 1,213,800
2022-08-16 2022-08-12 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
F - Taxes -7,257 67,743 -9.68 38.02 -275,911 2,575,589
2022-08-16 2022-08-12 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 45,000 75,000 150.00 4.75 213,750 356,250
2022-08-16 2022-08-12 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 20,000 30,000 200.00 3.10 62,000 93,000
2022-03-14 2022-03-10 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 65,000 65,000
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -40,000 0 -100.00
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -2,500 0 -100.00
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
S - Sale -31,048 10,000 -75.64 30.54 -948,206 305,400
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
S - Sale -1,805 41,048 -4.21 30.62 -55,269 1,256,890
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
F - Taxes -8,952 42,853 -17.28 30.23 -270,619 1,295,446
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 40,000 51,805 338.84 6.76 270,400 350,202
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
F - Taxes -695 11,805 -5.56 30.23 -21,010 356,865
2022-03-08 2022-03-07 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 2,500 12,500 25.00 8.40 21,000 105,000
2022-03-08 2022-03-04 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
M - Exercise -25,000 0 -100.00
2022-03-08 2022-03-04 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
S - Sale -18,315 10,000 -64.68 30.79 -563,919 307,900
2022-03-08 2022-03-04 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
F - Taxes -6,685 28,315 -19.10 31.42 -210,043 889,657
2022-03-08 2022-03-04 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
M - Exercise 25,000 35,000 250.00 8.40 210,000 294,000
2021-03-15 2021-03-12 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 65,000 65,000
2020-03-13 2020-03-12 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 65,000 65,000
2019-09-18 2019-09-16 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 40,000 40,000
2018-03-13 2018-03-12 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2017-10-24 2017-10-23 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 20,000 20,000
2017-08-17 2017-08-15 4 XENE Xenon Pharmaceuticals Inc.
Common Shares
P - Purchase 10,000 10,000 2.48 24,824 24,824
2017-03-14 2017-03-13 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 27,500 27,500
2016-02-09 2016-02-08 4 XENE Xenon Pharmaceuticals Inc.
Stock Option (Right to Buy)
A - Award 40,000 40,000
2016-02-09 3 XENE Xenon Pharmaceuticals Inc.
No securities are beneficially owned
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)